文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

高剂量维生素D3联合标准治疗用于转移性结直肠癌:SOLARIS随机临床试验

Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703).
PubMed 文献 · JAMA · 2026-01-01

这项3期双盲随机试验纳入455例初治转移性结直肠癌患者,比较标准方案联合高剂量或标准剂量维生素D3的疗效。

要点

  • 高剂量维生素D3未改善初治转移性结直肠癌患者的无进展生存期。
  • 客观缓解率与总生存期在两组间无显著差异。
  • 高剂量与标准剂量维生素D3的安全性特征相似。

核心结论

  • 在初治转移性结直肠癌患者中,标准化疗联合贝伐珠单抗基础上加用高剂量维生素D3,相比标准剂量维生素D3,未改善无进展生存期。

研究设计与样本

  • 双盲3期随机临床试验,2019年10月至2022年12月在美国通过国家临床试验网络开展,纳入455例初治转移性结直肠癌患者,数据库冻结于2024年7月15日。

主要发现

  • 最常见≥3级不良事件包括中性粒细胞减少(高剂量组67例[32%] vs 标准剂量组62例[30%])和高血压(42例[20%] vs 49例[23%]),组间无临床意义差异。

关键数值与推荐

  • 高剂量维生素D3方案:8000 IU/日×14天负荷剂量,随后4000 IU/日;标准剂量为400 IU/日。
  • 化疗方案为mFOLFOX6或FOLFIRI联合贝伐珠单抗,每2周一次。
  • 主要终点为无进展生存期,采用非分层log-rank检验。

临床怎么用

  • 对于初治转移性结直肠癌患者,不应在标准化疗联合贝伐珠单抗基础上常规加用高剂量维生素D3以期望改善生存结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In a phase 2 randomized clinical trial, high-dose vitamin D3 added to standard treatment improved progression-free survival (PFS) compared with standard-dose vitamin D3 in patients with metastatic colorectal cancer (mCRC). OBJECTIVE: To determine if high-dose vitamin D3 added to standard chemotherapy improves outcomes in patients with previously untreated mCRC. DESIGN, SETTING, AND PARTICIPANTS: Double-blind phase 3 randomized clinical trial enrolling 455 patients with previously untreated mCRC, conducted in the US through the National Clinical Trials Network from October 2019 to December 2022 (database freeze: July 15, 2024). INTERVENTIONS: mFOLFOX6 (modified FOLFOX6 [5-fluorouracil, leucovorin, oxaliplatin]) or FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab every 2 weeks with either high-dose vitamin D3 (8000 IU daily × 14 days as loading dose followed by 4000 IU daily) or standard-dose vitamin D3 (400 IU daily) until disease progression, intolerable toxicity, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The primary end point was PFS assessed by the unstratified log-rank test. Secondary end points included objective response rate, overall survival, and toxicity. Prespecified subgroup analyses of PFS were performed according to known prognostic factors. RESULTS: Among 455 randomized patients (median age, 59 years; 181 [40%] female) with median follow-up 20 months, the median PFS for high-dose vitamin D3 (n = 228) was 11.8 months (95% CI, 10.3-13.3) vs 10.3 months (95% CI, 9.4-12.2) for standard-dose vitamin D3 (n = 227) (1-sided log-rank P = .25). There were no significant differences in objective response rate between high-dose and standard-dose vitamin D3 (51% [95% CI, 44%-58%] vs 44% [95% CI, 37%-50%], respectively; P = .12), or in overall survival (median, 25.6 vs 27.0 months; 1-sided log-rank P = .66). There were no clinically meaningful differences in the most common grade 3 or greater adverse events between the high- and standard-dose groups, including neutropenia (n = 67 [32%] vs n = 62 [30%]) and hypertension (n = 42 [20%] vs n = 49 [23%]) or in incidence of vitamin D-associated toxicities. CONCLUSIONS AND RELEVANCE: Among patients with previously untreated mCRC, addition of high-dose vitamin D3, vs standard-dose vitamin D3, to standard chemotherapy plus bevacizumab did not improve PFS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04094688.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ng K, Ou FS, Zemla T, et al. Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703). JAMA. 2026. PMID: 42545685. doi:10.1001/jama.2026.9350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。